Overview

Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

Status:
Completed

Trial end date:
2015-04-21

Target enrollment:

Participant gender:

Summary

This is a single-dose, randomized, placebo-controlled, 3-way crossover study of 2 dosage strengths of lemborexant (5 mg and 10 mg) in participants with insomnia disorder.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Flurazepam
Lemborexant